Researchers uncovered evidence of vivax malaria becoming resistant to standard treatment with chloroquine, a problem exacerbated by the Plasmodium vivax parasite’s tendency to lie dormant in the liver for long periods before causing recurrent infections.
“Our results show chloroquine is currently given in lower doses than recommended, with as many as 35 percents of patients in trials given less than the World Health Organization (WHO) recommended 25 mg per kg.
“We also know from our analysis that these patients are more likely to fail treatment.”
If left untreated, Plasmodium vivax malaria leads to severe disease and death. “The study highlights the need for clinicians in affected areas to provide radical cure to kill the blood and liver stage of the vivax parasite and ensure patients can recover quickly.
“We also want to prevent transmission of the parasite to other people and reduce the global burden of this disease,” Commons said.
Source: Nigerianews